<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[22, 25] efficacy and safety<br>[63, 66] measurable and assessable<br>[100, 102] platinum sensitivity<br>[109, 112] bulky disease.<br>[140, 146] overall progression-free survival rates<br>[158, 161] overall response rates<br>[178, 182] Median overall survival times<br>[203, 212] significant benefit from PLD for progression-free survival<br>[230, 233] overall survival,<br>[261, 265] nonstatistically significant survival trend<br>[274, 277] Severe hematologic toxicity<br>[290, 301] dosage modification, or growth factor or blood product utilization.<br>[304, 315] comparable efficacy, favorable safety profile, and convenient dosing support<br></td>
<td width=33%>
[140, 146] overall progression-free survival rates<br>[158, 161] overall response rates<br>[179, 182] overall survival times<br>[208, 212] progression-free survival<br></td>
<td width=33%>
[22, 25] efficacy and safety<br>[63, 66] measurable and assessable<br>[109, 112] bulky disease.<br>[140, 146] overall progression-free survival rates<br>[158, 161] overall response rates<br>[178, 182] Median overall survival times<br>[203, 212] significant benefit from PLD for progression-free survival<br>[230, 233] overall survival,<br>[262, 265] significant survival trend<br>[274, 277] Severe hematologic toxicity<br>[290, 301] dosage modification, or growth factor or blood product utilization.<br>[304, 315] comparable efficacy, favorable safety profile, and convenient dosing support<br></td>
</tr>
